Farabi Pharmaceutical Company

What Farabi Pharmaceutical Company does

Farabi Pharmaceutical Company (شرکت داروسازی فارابی) is one of Iran's largest and most modern pharmaceutical manufacturers, operating as a public joint stock company (TSE ticker: Dafara) since becoming operational in Dey 1371 (December 1992/January 1993). The company's core technology is a 50,000 sqm manufacturing complex built on 40 hectares in Isfahan, with all production lines GMP-certified by the Iran Food and Drug Organization and an Integrated Management System aligned to ISO 9001:2015, ISO 14001:2015, and ISO 45001. Farabi produces generic pharmaceuticals across 12 therapeutic categories — antibiotics (penicillins, cephalosporins, macrolides, fluoroquinolones), antivirals, nutritional supplements, cardiovascular, diabetes, neurological/psychiatric, digestive, pain management, cold/allergy, lipid/cholesterol, sexual rehabilitation, kidney/prostate, and anti-migraine — in multiple dosage forms including capsules, tablets, coated tablets, and oral suspensions. The company is recognized as a leader in Iran's antibiotic category and received Export Company of the Year from the Isfahan Chamber of Commerce.

Farabi's business model centers on volume manufacturing and sale of generic pharmaceuticals through a sales-led motion. Pricing is administered under the Iran Food and Drug Organization, and distribution flows primarily through Hejrat Distribution Company to Iranian pharmacies and hospitals, with a separate export channel serving international markets. The company is a subsidiary of Tamin Pharmaceutical Investment Company (Tpico/TIPO), itself part of the Social Security Investment Company (Shasta), which provides strategic direction, capital, and preferential access to Social Security Organization healthcare purchasing. Annual shareholders' assemblies are well-attended (74% participation at FY1402 AGM), and the company has distributed 90% of FY1401 earnings as dividends (4,214 Rials/share), reflecting cash-generative operations under Iranian regulatory pricing.

The customer base is primarily institutional and domestic: the Iranian healthcare system (hospitals, pharmacies, clinics, end patients) and Social Security Organization beneficiaries, supplemented by international export markets via direct sales partnerships. Distribution is concentrated through Hejrat domestically, while the parent Tamin structure provides embedded demand from Social Security channels. Reported monthly sales have reached record levels (e.g., 80 billion Tomans in Dey month, second in Iranian pharma industry by sales), with one period showing 179% YoY sales growth. Farabi also collaborates with Isfahan University of Medical Sciences on pharmacy internships and joint research, and is a member of the National Production Support Festival ecosystem.

Name

Farabi Pharmaceutical Company

Legal name

Farabi Pharmaceutical Company (شرکت داروسازی فارابی)

Website

https://farabipharma.ir

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• Antibiotic manufacturing
• Nutritional supplements
• Antiviral medications
• Pharmaceutical production

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Farabi Pharmaceutical Company generates revenue through the manufacture and sale of pharmaceutical products including antibiotics, supplements, cardiovascular drugs, diabetes medications, neurological/psychiatric medications, and other therapeutic categories. The company produces various dosage forms including capsules, tablets, coated tablets, and oral suspensions.
2. Pharmaceutical Exports: The company exports pharmaceutical products to international markets as indicated by dedicated export product pages and export market sections on their website.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Farabi Pharmaceutical Company manufactures and distributes generic pharmaceutical products including antibiotics (penicillins, cephalosporins, macrolides, fluoroquinolones), antivirals, and nutritional supplements (iron, calcium, glucosamine) across multiple therapeutic categories. The company produces capsules, tablets, coated tablets, and oral suspensions at a 50,000 sqm GMP-certified facility on 40 hectares in Isfahan, supplying pharmacies, hospitals, and international export markets.

Product overview

Farabi Pharmaceutical Company is a large-scale pharmaceutical manufacturer with a diversified portfolio of generic drugs and nutritional supplements. The company produces antibiotics (penicillins, cephalosporins, macrolides, fluoroquinolones), antivirals (acyclovir), and nutritional supplements (iron, calcium, glucosamine). It operates as a publicly listed company (TSE: Dafara) and is a subsidiary of Tamin Pharmaceutical Investment Company (TICO Holding), part of the Social Security Investment Organization. The company is positioned as Iran's largest oral antibiotic manufacturer, operating GMP-certified production lines across a 50,000 sqm facility on 40 hectares in Isfahan, operational since 1992.

Differentiator

Problem solved

Functional benefit

Products and services

• Amoxicillin (آموکسی سیلین)
• Ampicillin (آمپی سیلین)
• Co-Amoxiclav (کوآموکسی کلاو)
• Farmentin BD (فارمنتین بی دی)
• Farmentin ES-643 (فارمنتین ای اس 643)
• Faramox BD (فاراموکس بی دی)
• Cloxacillin (کلوگزاسیلین)
• Penicillin V Benzathine (پنی سیلین وی بنزاتین)
• Penicillin V Potassium (پنی سیلین وی کا)
• Cephalexin (سفالکسین)
• Cefixime (سفیکسیم)
• Farinat / Cefuroxime (فارینات)
• Clarithromycin (کلاریترومایسین)
• Erythromycin (اریترومایسین)
• Azithromycin (آزیترومایسین)
• Ciprofloxacin (سیپروفلوکساسین)
• Levofloxacin (لووفلوکساسین)
• Acyclovir (آسیکلوویر)
• Fefar (ففار)
• Calcifar (کلسی فار)
• Calcifar Plus (کلسی فار پلاس)
• Glucosamine Sulfate (گلوکزآمین سولفات)
• Glucosamine Sulfate-Chondroitin Sulfate (گلوکزآمین سولفات-کندرئیتین سولفات)

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered major and minor.

• Hejrat Distribution Company (شرکت پخش هجرت)majorChannel Partner/ Reseller/ DistributorHejrat is a key pharmaceutical distribution partner for Farabi. A synergy meeting was held between the senior management of both companies to strengthen their partnership and coordinate distribution efforts.
• Isfahan University of Medical Sciences (دانشگاه علوم پزشکی و خدمات بهداشتی، درمانی اصفهان)minorStrategic or Co-development PartnerFarabi collaborates with Isfahan University of Medical Sciences including pharmacy student internship programs and joint research initiatives. The company also has a relationship with Isfahan School of Pharmacy.

Scale indicators10 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Cipla: Major Indian global generic pharmaceutical manufacturer with leadership in antibiotics and respiratory/casics; comparable as a broad incumbent generic pharma player whose therapeutic mix and emerging-market focus overlap with Farabi's portfolio orientation.
• Dr. Reddy's Laboratories: Global Indian generic pharmaceutical manufacturer with strong positions in antibiotics, anti-infectives, and chronic disease medications; comparable as a broad incumbent whose emerging-market distribution and therapeutic breadth mirror Farabi's positioning.
• Aurobindo Pharma: Large-scale Indian generic manufacturer with leading positions in antibiotics, antivirals, and chronic disease categories; comparable as a broad incumbent whose product portfolio and scale-driven cost position mirror Farabi's generics-and-antibiotics focus.

Direct peers

• Alborz Darou Pharmaceutical Company: Iranian manufacturer of generic pharmaceuticals including antibiotics and supplements; comparable as a domestic Iranian generic pharma peer with overlapping therapeutic categories and similar distribution to pharmacies and hospitals.
• Shahid Darou (Darou Pakhsh Group subsidiary): Iranian manufacturer of generic antibiotics and pharmaceutical products; comparable as a domestic Iranian peer competing in the same antibiotic and chronic-disease categories served by Farabi.
• TPICO Holding subsidiaries (e.g., Exir, Sobhan Oncology): Other subsidiaries of Tamin Pharmaceutical Investment Company producing generic and specialty pharmaceuticals; comparable as sister companies operating under the same parent holding with overlapping distribution and product categories.
• Barakat Pharmaceutical Company: Iranian state-affiliated pharmaceutical producer focused on generic and essential medicines including antibiotics; comparable as a domestically-positioned large-scale generic manufacturer with similar go-to-market channels.
• Darou Pakhsh Pharma: One of Iran's largest pharmaceutical manufacturers producing a broad range of generic medicines including antibiotics, anti-infectives, and specialty drugs; directly comparable as a domestic Iranian large-scale generic pharma producer serving healthcare providers.
• Iran Darou: Established Iranian pharmaceutical manufacturer producing generic medicines across multiple therapeutic categories; comparable as a domestic Iranian generic pharma peer targeting the same hospital, clinic, and pharmacy channels.

Others

• Tamin Pharmaceutical Investment Company (TIPO): The parent holding company of Farabi and Iran's largest pharmaceutical investment group; comparable as the broader portfolio platform under which Farabi sits, with overlapping therapeutic categories across subsidiaries.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/farabipharm
• LinkedInlinkedin.com/company/farabi-pharma-company

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Farabi Pharmaceutical Company